Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.
) options ahead of good news on the biopharmaceutical company’s COVID-19 drug treatment may draw regulatory scrutiny, experts said.
Those gains were dwarfed by a price jump in bullish options which traded in unusually high volume just hours before the report and which more than doubled in value overnight. Early in the trading day on April 16, with Gilead shares hovering around $75, four large blocks of its options were purchased for about $1.5 million each. Those unusually large trades bet that Gilead’s shares would rise north of $80 to $87.50 by mid August.
“When there is a specific spike in the firm’s trading activity — right before a finding is announced — it can become a red flag to regulators,” he said.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
'I Just Couldn't Let Her Die Alone': Nurse FaceTimes COVID-19 Patient Through Final HoursCommentary: Linda Lombardi knew that her former patient had no family or close friends. So she used FaceTime to stay with her during her final hours in a special palliative care ward for COVID-19 patients. 'I just couldn't let her die alone,' she says.
Weiterlesen »
COVID-19 Takes Heavy Toll On People With Dementia — Even Those Who SurviveMany people with dementia who fall ill can’t express their symptoms, and early coronavirus markers may look similar to their other pre-existing conditions. That means COVID-19 can go undiagnosed in the early stages. hereandnow
Weiterlesen »
The world's new Covid-19 epicenter could be the worst yetAs new deaths and cases fall in the United States, Europe and Asia, Latin America now stands as the world's sole region where the outbreak is unequivocally reaching new heights.
Weiterlesen »
In The Battle Against COVID-19, A Risk Of 'Vaccine Nationalism'Both President Trump and China's President Xi Jinping have faced criticism for their handling of the coronavirus outbreak. Success with a vaccine at home could make up for the earlier shortcomings.
Weiterlesen »